HTA92 10 Years of AMNOG: Importance of Real-World Evidence Studies in the German Benefit Assessment Process von Seidel, K, Schnaidt, S, Viering, T, Löpmeier, JF, Borchert, K, Jacob, C

Volltext

HTA183 AMNOG Benefit Assessment in Germany: Outcomes From 2011 to 2022 von Pägelow, D, Fischer-Huchzermeyer, S, Löpmeier, JF, Schwerbel, K, Kulp, W

Volltext

HTA203 Methods Used for Trend Estimation of Epidemiological Figures in the German Benefit Assessment (AMNOG) Process von Schnaidt, S, Seidel, K, Viering, T, Löpmeier, JF, Borchert, K, Jacob, C

Volltext

HTA128 Reassessment of Orphan Drugs After Exceeding the 50 Mio. Euro Revenue Threshold: Effects on Added Benefit and Price Discount von Michel, RO, Löpmeier, JF, Ingendoh-Tsakmakidis, A, Italia, N, Kulp, W

Volltext